NTRK1 and breast carcinoma: Most of the antibody‐derived probes explored in clinical practice are targeting cluster of differentiation antigens,[17, 36] receptor tyrosine kinases,[14] and enzymes.[37] Recent advances have shown that TF is a promising diagnostic marker for several categories of malignancies, including pancreatic cancer,[32, 34] and breast cancer.[33] In this work, we first reported the abundant expression of TF in advanced thyroid cancer cell lines, indicating the potential of TF as a biomarker for advanced thyroid cancers.